ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:

Dictionar de medicamente online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Dictionar medical online

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Puteti trimite articole cu tema medicala la
adresa de email

Solutie antistress!
Construieste poduri :)
Joc, Construieste podul, Cargo Bridge

Prinde pisica neagra :)
Prinde pisica neagra- Chat Noir - Flash game

Developing Immunotherapy For Alzheimer's Disease, Eisai Announces Strategic Alliance With BioArctic Neuroscience

Tokyo, Japan, - (JCN Newswire) - Eisai Co, Ltd and BioArctic Neuroscience Inc announced that on August 24, they signed a strategic alliance agreement to develop an immunotherapy for Alzheimer's disease. Based on this agreement, Eisai will obtain first right of refusal for drug candidates developed resulting from the research.

BioArctic Neuroscience Inc. is a biotech company that was established in January, 2003, with the aim of industrial application of Alzheimer's disease research by Prof. Lannfelt, Uppsala University, who is an internationally well-known Alzheimer's disease researcher. Currently, Prof. Lannfelt's group is conducting basic research to further advance knowledge about the Arctic mutation of A, for immunotherapy in Alzheimer's disease. Arctic mutation of A is a mutation discovered by Prof. Lannfelt in 2001. It causes familial Alzheimer's disease and pathophysiologically shows very similar lesions to those found in non-familial Alzheimer's disease. In this respect, Arctic mutation of Ais expected to be applied to evaluate efficacy in a wide range of Alzheimer's disease treatment. The research will be carried out mainly by BioArctic Neuroscience and Prof. Lannfelt.

Eisai actively puruses alliances with outside organizations in order to expand its product line-up in the neurology arena, one of the company's franchise areas. With the BioArctic Neuroscience agreement, Eisai wishes to gain a new immunotherapy in drug treatment of Alzheimer's disease cut out by Aricept, and lead to a novel, beneficial treatment for Alzheimer's disease.

About Eisai Co., Ltd.

Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of nearly $4.5 billion in fiscal 2003/4, with approximately 15 percent of sales spent for research and development.

View Eisai Co., Ltd. 's Company Profile

Copyright(C) 2005 www.japancorp.net JCN Newswire. A division of Japan Corporate News Network KK. All rights reserved

View drug information on ARICEPT.





Dezvoltarea imunoterapie Pentru Boala Alzheimer, Eisai Announces alianþã strategicã Cu BioArctic Neuroscience - Developing Immunotherapy For Alzheimer's Disease, Eisai Announces Strategic Alliance With BioArctic Neuroscience - articole medicale engleza - startsanatate